levofloxacin has been researched along with enoxacin in 21 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (enoxacin) | Trials (enoxacin) | Recent Studies (post-2010) (enoxacin) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 734 | 74 | 122 |
| Protein | Taxonomy | levofloxacin (IC50) | enoxacin (IC50) |
|---|---|---|---|
| V-type proton ATPase subunit B, brain isoform | Homo sapiens (human) | 10 | |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, S; Cui, S; McDermott, PF; Meng, J; Paulsen, I; White, DG; Zhao, S | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Gao, F; Wang, T; Xiao, J; Zhang, X | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Takayama, S; Wagai, N; Yoshida, M | 1 |
| Aoki, H; Fujisawa, C; Hakusui, H; Kurata, T; Ohshima, Y; Okazaki, O; Tanaka, M | 1 |
| Schaeffer, AJ | 1 |
| Ono, C; Tanaka, M | 1 |
| Dawe, RS; Ferguson, J; Ibbotson, SH; Sanderson, JB; Thomson, EM | 1 |
| Hong, JW; Hu, CQ; Sheng, LS | 1 |
| Guo, H; Li, J; Liu, Z; Nie, S; Pan, W | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Kodawara, T; Masada, M; Masuda, S; Matsubara, K; Nakamura, T; Yano, Y | 1 |
| Chau, TTH; Heemskerk, D; Hien, TT; Phuong, PN; Pouplin, T; Tho, NDK; Thuong Thuong, NT; Thwaites, GE; Van Toi, P | 1 |
| Fang, G; Gao, J; Gao, X; Li, J; Liu, H; Liu, X; Lu, X; Tang, Y; Wang, J | 1 |
| Beare, PA; Bloom, ME; Broeckel, RM; Flather, DP; Kendall, BL; Morris, CN; Offerdahl, DK; Scroggs, SLP | 1 |
3 review(s) available for levofloxacin and enoxacin
| Article | Year |
|---|---|
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
Quinolone antibiotics.
Topics: | 2019 |
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Norfloxacin; Ofloxacin; Quinolones; Urinary Tract Infections | 2002 |
2 trial(s) available for levofloxacin and enoxacin
| Article | Year |
|---|---|
A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity.
Topics: Adult; Anti-Bacterial Agents; Asian People; China; Dermatitis, Phototoxic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxacin; Female; Fluoroquinolones; Follow-Up Studies; Humans; Japan; Levofloxacin; Light; Male; Middle Aged; Ofloxacin; Scotland; Single-Blind Method; Skin Tests; Statistics, Nonparametric; White People | 2003 |
High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis.
Topics: Adult; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Drug Stability; Enoxacin; Humans; Levofloxacin; Limit of Detection; Linear Models; Reproducibility of Results; Solid Phase Extraction; Spectrometry, Fluorescence; Tuberculosis, Meningeal | 2017 |
16 other study(ies) available for levofloxacin and enoxacin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
Topics: Animals; Anti-Infective Agents; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Gene Targeting; Genes, Bacterial; Mutation; Salmonella Infections, Animal; Salmonella typhimurium | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Phototoxic potential of the new quinolone antibacterial agent levofloxacin in mice.
Topics: Animals; Anti-Infective Agents; Enoxacin; Female; Levofloxacin; Light; Mice; Mice, Inbred BALB C; Ofloxacin; Photosensitivity Disorders | 1992 |
Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide.
Topics: Aluminum Hydroxide; Animals; Buffers; Chemical Phenomena; Chemistry, Physical; Chloroform; Drug Interactions; Enoxacin; Intestinal Absorption; Levofloxacin; Male; Norfloxacin; Ofloxacin; Phosphates; Rats; Rats, Sprague-Dawley | 1993 |
Binding characteristics of fluoroquinolones to synthetic levodopa melanin.
Topics: Binding Sites; Chloroquine; Ciprofloxacin; Drug Interactions; Enoxacin; Fluoroquinolones; Levodopa; Levofloxacin; Melanins; Monophenol Monooxygenase; Norfloxacin; Ofloxacin; Quinolones; Timolol | 2003 |
[Analysis of the response factors of different quinolones detected by evaporative light-scattering detector].
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Light; Linear Models; Ofloxacin; Quinolones | 2003 |
Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes.
Topics: 1-Octanol; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cornea; Drug Carriers; Enoxacin; Ethylene Glycols; Eye; Fluoroquinolones; Gatifloxacin; In Vitro Techniques; Irritants; Levofloxacin; Ofloxacin; Oxaprozin; Permeability; Propionates; Rabbits; Ribavirin; Water | 2006 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Enoxacin; Enterohepatic Circulation; Glucuronidase; Glucuronides; Immunosuppressive Agents; In Vitro Techniques; Inhibitory Concentration 50; Levofloxacin; Mycophenolic Acid; Ofloxacin; Phenolphthaleins; Time Factors | 2014 |
Upconversion particle@Fe
Topics: Animals; Biosensing Techniques; Ciprofloxacin; Enoxacin; Enrofloxacin; Erbium; Fishes; Fleroxacin; Fluorescent Dyes; Fluorides; Fluoroquinolones; Levofloxacin; Magnetite Nanoparticles; Molecular Imprinting; Quinolones; Reproducibility of Results; Seafood; Ytterbium; Yttrium | 2018 |
Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Animals; Anti-Bacterial Agents; Antiviral Agents; Cell Line; Chlorocebus aethiops; Ciprofloxacin; Coronavirus Infections; COVID-19 Drug Treatment; Enoxacin; Fluoroquinolones; Humans; Levofloxacin; Middle East Respiratory Syndrome Coronavirus; Moxifloxacin; SARS-CoV-2; Vero Cells | 2020 |